The Government of India has taken up a number of initiatives to create an ecosystem that fosters manufacturing and have identified a few key areas. ‘Make in India’ is one of the key programmes launched by the government to boost the economy and the aim is to transform India into a global manufacturing hub. This is an eloquent testimony to the competence of the Indian pharma sector in terms of quality and pricing. The Minister for Excise and Liquor Prohibition, Uttar Pradesh, Shri Jai Parata Singh and several dignitaries from fields of medicine, pharmaceuticals and other were present on the occasion. Saying that pharmaceuticals was a priority area for Government, Shri Naidu stressed the need to further harness the potential of the sector by use of technology, innovation and research. To bring down the healthcare budget of every citizen of India through providing Quality generic Medicines at Affordable Prices.
The scheme is being implemented by the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (BPPI), under the administrative control of the Department of Pharmaceuticals and the Ministry of Chemicals and Fertilisers. As of FY23, it covers 1,759 medicines and 280 surgical & consumables in all key therapeutic categories such as anti-infective, anti-allergic, anti-diabetics, cardiovascular, anti-cancers, and gastrointestinal medicines. India should also enter into international partnerships and agreements in the pharmaceutical sector so that we learn from the best and adopt the best protocols and practices.
As of December 2023, the government has already established 10,006, with 206 medicines and 13 surgical equipment have been newly added this year in Jan Aushadhi stores in the country. Generic medicines play a crucial role in making healthcare more affordable and accessible. They help reduce overall healthcare costs, promote health equity, and support government initiatives like the Pradhan Mantri Jan Aushadhi Yojana (PMJAY). Yes, generic medicines are required to meet the same safety, quality, and efficacy standards as branded medicines. They must be approved by regulatory authorities like the Central Drugs Standard Control Organization (CDSCO) in India. The availability of generic drugs fosters competition among pharmaceutical companies, which drives innovation and encourages more affordable pricing across the board.
Many rural pharmacies may not stock a wide range of generics due to logistical challenges or low demand, leading patients to rely on more expensive branded alternatives. While generic medicines have played a transformative role in improving healthcare accessibility and affordability, they also face several challenges in India. These issues stem from quality control, regulatory oversight, and consumer perception, all of which can hinder the widespread acceptance and effectiveness of generics in the country. Today, India is one of the world’s largest producers and exporters of generic medicines, accounting for about 20% of the global supply. Indian pharmaceutical companies manufacture a wide range of generic drugs, including antibiotics, antivirals, and medicines for chronic diseases like diabetes and hypertension.
Generic medicines can only be produced after the patent on the brand-name drug has expired. This allows multiple manufacturers to create the same medicine, increasing competition and driving prices down. Generic drugs are tested rigorously to ensure they meet the same safety and efficacy standards as brand-name drugs. FDA (Food and Drug Administration) or India’s CDSCO (Central Drugs Standard Control Organization) ensure that generic drugs adhere to strict guidelines before they are approved for public use. A landmark moment in India’s pharmaceutical history came with the Indian Patents Act of 1970.
Yes, Medkart Pharmacy offers a diverse range of over-the-counter products to meet common health needs. We at Medkart Pharmacy dream of making sure that everyone is truly aware of Generic Medicines. You can also buy essential medical products, branded or generic medicines online from medkart official website. Increasing the number of Jan Aushadhi Kendras across India, especially in rural areas, can ensure the availability of generic medicines to even the most underserved populations. As India continues to address its healthcare challenges, the role of generic medicines will remain vital in ensuring that all individuals have access to the medications they need for maintaining good health. Despite these changes, Indian pharmaceutical companies continued to thrive by focusing on producing generics for medicines whose patents had expired and exporting them worldwide.
These programmes benefit more than 15 million people who are living with HIV/AIDS. This allowed for the production of low-cost, generic versions of medicines that were patented in other countries. Generic drugs have the same Abiraterone price philippines active ingredients as the brand-name drugs, ensuring the same therapeutic benefits. However, the inactive ingredients (such as fillers, colorants, or preservatives) may vary, but they do not affect the drug’s performance.
The Vice President of India, Shri M. Venkaiah Naidu has called up on the pharmaceutical industry to work towards making India an International Capital of Generic Medicines. With years of experience and partnerships across the pharmaceutical industry, we guarantee timely and secure delivery. We provide a wide range of specialty drugs, from anti-viral treatments to nephrology drugs, addressing complex medical needs.
Under the Scheme, dedicated outlets known as Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) are opened to provide generic medicines at cheaper rates to the citizens. Government has set a target to open 10,500 Kendras across the country by March 2025. As a leading Jan Aushadhi supplier, we are committed to making high-quality, affordable medicines available to healthcare providers and patients across India. Contact us today for bulk orders and learn more about how we support the mission of affordable healthcare.
There is still a large section of the population which finds it difficult to afford these high-priced medicines. According to World Health Organization estimates (2008), 65% of India‟s population does not have access to modern health care. Since 80% of out-patient care and 60% of in-hospital care occurs at private hospitals in India, households are exposed to a private-sector market to buy drugs (Public Health Foundation of India, 2012). According to NSO estimates, upto 79% of health care expenses in rural areas are due to the cost of medicines. Though the government has encouraged the prescription of generic medicines, many doctors in India still prefer prescribing branded drugs due to established relationships with pharmaceutical companies or doubts about the quality of generics. While the Pradhan Mantri Jan Aushadhi Yojana (PMJAY) has promoted the use of generic medicines, there is still a lack of awareness about the benefits of generics among the general public and even some healthcare professionals.
Our generic drugs are priced competitively, without compromising quality, making life-saving treatments accessible. President’s Emergency Plan for AIDS Relief (PEPFAR), UNITAID and others, rely on the country’s generic antiretrovirals for the programs they support. Today, India is the world’s primary source of affordable HIV medicines as it is one of the few countries with the capacity to quickly produce newer HIV drugs as generics.
From legislative changes in the 1970s to the expansion of the global generics market, India’s pharmaceutical industry has grown into a powerhouse. Today, India stands as a leader in the global generic drug market, providing life-saving medicines to millions of people worldwide, while continuing to be a vital player in making healthcare affordable for all. Yet, the country’s marginalised populations have limited access to medicines as branded medicines are sold at significantly higher prices than their unbranded generic equivalents, despite being identical in the therapeutic value. Therefore, there is an urgent need to ensure the availability of cheaper generics to citizens; this is in the best interest of these populations.
Unlike branded medicines, which spend significantly on advertising and promotion, generic drugs rely less on branding and more on their efficacy, resulting in reduced costs. The government has proposed amendments to the Drugs and Cosmetics Rules to ensure availability of generic drugs at reasonable prices and to promote the use of generic medicines. To ensure high quality, medicines are procured from WHO Good manufacturing practice (GMP), Current Good Manufacturing Practice and CPSUs manufacturers for supplying to Pradhan Mantri Bhartiya Janaushadhi Kendras. Only after being certified by these laboratories, medicines are dispatched to C&F agents, Distributors and JAKs. In contrast to India’s stricter patentability criteria, the U.S. allows the practice of ‘evergreening’ that helps delay generic competition and keeps prices high.
The article discusses the types of medicines available through the scheme, quality standards, certification process, pricing, and benefits to the general public. The article also highlights the challenges faced by the PMBJP scheme in ensuring the availability and accessibility of medicines in remote areas. Furthermore, the article discusses the potential of PMBJP to expand and cover more medicines and medical devices, as well as its role in achieving the goal of universal health coverage in India. Generic medicines play a key role in government healthcare initiatives such as the Pradhan Mantri Jan Aushadhi Yojana (PMJAY), which aims to make essential medicines affordable and accessible to all citizens.
To address this issue government central government started Jan Aushadhi (Medicine for the masses) programme in 2008 with the objective of providing quality medicines at affordable prices. Despite their potential to make healthcare affordable and accessible, generic medicines in India face multiple challenges. Addressing issues related to quality assurance, regulatory enforcement, public awareness, and the perception of generics is essential for improving their acceptance. By overcoming these obstacles, India can better harness the power of generic drugs to benefit its healthcare system and ensure equitable access to essential medicines. By the 1990s, India had become one of the largest suppliers of generic medicines globally.
In order to ensure quality of the products, PMBI procures medicines only from World Health Organization – Good Manufacturing Practices (WHO-GMP) certified suppliers. Apart from this, each batch of drug is tested at laboratories accredited by ‘National Accreditation Board for Testing and Calibration Laboratories (NABL). Only after passing the quality tests, the medicines are dispatched to PMBJP Kendras. The government has also launched a mobile application ‘Janaushadhi Sugam’ that provides information to public about location of kendras, help them search Janaushadhi medicines and compare the maximum retail price of Generic vs. Branded medicines, etc.
The act abolished product patents on drugs and allowed only process patents for a limited period. This meant that Indian pharmaceutical companies could legally reverse-engineer and produce generic versions of patented drugs by using a different manufacturing process. Making quality medicines available at affordable prices for all, particularly the poor and disadvantaged, through exclusive outlets „Jan Aushadhi Medical Store“, so as to reduce out of pocket expenses in healthcare. So it is not only the responsibility of the government to support generics, but we all should also take the initiative to support generics. Recently, these initiatives have already been started by a few state governments in India. Low-cost, generic medicines produced in India are helping millions of people across the world get affordable, high-quality medication.
By offering low-cost, high-quality alternatives to branded drugs, generic medicines help reduce healthcare costs and improve access to treatments, supporting the government’s broader goal of universal healthcare. India is one of the world’s largest producers of generic drugs, with Indian pharmaceutical companies supplying over 50% of global demand for various vaccines and 40% of the generic drugs used in the United States. The Indian government has taken several initiatives to promote the use of generic medicines domestically, including the Pradhan Mantri Jan Aushadhi Yojana (PMJAY), which provides quality generic medicines at affordable prices. India’s generic medicines are not only essential for its own population but also play a critical role in global healthcare. The country’s pharmaceutical sector has become a reliable source of affordable medicines for developed and developing countries alike. The history of generic medicines in India reflects the country’s commitment to ensuring affordable and accessible healthcare.
This competition, along with the lack of R&D and marketing costs, significantly reduces the price of generic medicines. Generic medicines are vital for providing affordable healthcare to millions in India. With initiatives like the Pradhan Mantri Jan Aushadhi Yojana, the country is moving towards a future where quality medicines are available to all, regardless of financial constraints. However, more awareness, policy changes, and efforts to improve public perception are needed to fully unlock the potential of generic medicines in India. Indian manufacturers, with their reverse engineering skills, were the first to market low-cost versions of the life-saving cancer (Imatinib) and HIV drugs (Zidovudine) within a few years of their US launch. The Scheme is being implemented through the Bureau of Pharma PSUs of India (BPPI), under the administrative control of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India.
In India, generic pharmaceuticals are crucial to lowering healthcare costs and increasing access. We may better appreciate their vital function in the healthcare system if we are aware of their advantages, difficulties, and legal environment. When looking for effective and affordable treatment choices, Dr. Best advises patients and healthcare professionals to explore generic options. In India, generic medicine sales appear to be on the rise, as long as the government continues to encourage them. Over the years, India has developed a strong capability in producing quality branded and generic medicines in most of the therapeutic categories, evolving from a mere Rs 1,500 crores industry in 1980 to a more than Rs 1,19,000 crores industry in 2012. Despite government efforts to promote generic medicines through initiatives like Jan Aushadhi Kendras, the availability of generics in rural and remote areas is still limited.
This leads to lower costs because generic manufacturers do not incur the high expenses of research and marketing. As of July 2024, ~13,113 Pradhan Mantri Bhartiya Janaushadhi Pariyojana Kendras were operational in India. Under the PMBJP Kendras, a medicine is priced on the principle of a maximum of 50% of the average price of the top three branded medicines. Therefore, the cost of Jan Aushadhi medicines is cheaper by ~50% and in some cases, by 80-90% of the market price for branded medicines. Rural health programmes, lifesaving drugs and preventive vaccines should also receive attention from policy makers and Pharma companies alike.
It is quite heartening to note that the Pharma sector is out-performing most other sectors in achieving consistently high growth. The Pharma industry has posted a robust, double-digit growth over the last few years. The industry was worth US $36.7 Billion in 2017 and is projected to grow to US $55 Billion by 2020. The Atharva veda is a treasure trove of knowledge and wisdom in the field of medicine. It is clear that since the ancient times India had a very systematic, scientific and rational approach to the treatment of diseases. I have been buying prostate cancer medicine Abiraterone for my dad regularly with them.
Indian pharmaceutical companies started exporting generic drugs to developing countries that were grappling with the high cost of healthcare. The country earned the title of the “pharmacy of the developing world”, providing essential medicines at low prices to countries in Africa, Asia, and Latin America. In recent years, generic medicines in India have emerged as a powerful tool in making healthcare more affordable and accessible to millions of people. With rising healthcare costs, the availability of generic drugs has provided relief to patients by offering low-cost alternatives without compromising on quality. This article explores the significance of generic medicines in India, their role in the healthcare system, and why they are key to reducing out-of-pocket expenditure on healthcare. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a campaign launched by the Department of Pharmaceuticals to provide quality medicines at affordable prices to the masses.
This makes them more accessible to patients and healthcare providers across different regions. The scheme was a major milestone in making healthcare accessible to all citizens, especially in rural and underprivileged areas. PMJAY also helped raise awareness about the benefits of generic medicines, countering the perception that generics are of lower quality. The AIDS crisis in the late 1990s further highlighted India’s role in the global healthcare system. Indian companies, particularly Cipla, gained international recognition by producing affordable generic antiretroviral (ARV) drugs to treat HIV/AIDS, which significantly lowered the cost of treatment in Africa and other developing regions.
ConclusionIn conclusion, the PMBJP scheme has been instrumental in making quality generic medicines available and affordable to all sections of society, especially the economically weaker sections in India. The scheme has been successful in increasing the accessibility of medicines to the masses and has helped in reducing healthcare costs for individuals and the government. However, there are still challenges that need to be addressed, such as ensuring the availability and accessibility of medicines in remote areas. The potential of the PMBJP to expand and cover more medicines and medical devices is promising, and it can play a crucial role in achieving the goal of universal health coverage in India. AbstractThis article provides an overview of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) scheme in India. The PMBJP scheme aims to make quality generic medicines available and affordable to all sections of society, especially the economically weaker sections.
With the vision to provide quality generic medicines to all citizens, the government’s Pradhan Mantri Bhartiya Janaushadhi Pariyojana brings this concept to reality. Out of Pocket expenditure on medicines constitutes more than 50% of healthcare expenditure in India. The poor are most affected as branded medicines are expensive and treatments involving the use of such medicines pushes them further into poverty.
Hatte hier mein erstes spiel und wurde angefixt.
Die Leihausrüstung war ok lässt aber zu wünschen übrig.
Kimme und Korn waren verschlissen das sie sich nicht instellen ließen.
Schutzbrille war immer beschlagen und die Maske hatte auch ihre Tage hinter sich das sie nur mäßig hielt. Für das erste mal war es aer vollkommen in Ordnung. Im Preis der Leihausrüstung war auch Tranjacke und Tarnhose enthalten.
Die Preise stimen mit der Webseite hier nicht mehr überein, anscheinend schon länger nicht.
Die website existiert nicht mehr und auf Facebook steht, dass es den park garnich mehr gibt
Die Area M war die erste Airsoft Area, auf der ich jemals gespielt habe!!!
Und jetzt bin ich immer noch der Meinung, dass es die beste Map war, auf der ich je gespielt habe! Hier kann man sowohl u, als auch ü 18 sehr viel Spaß haben!
Sowohl die Spieler als auch das Personal wahren immer sehr freundlich und man kann, auch wenn man alleine kommt, eine Gruppe finden, die einem Sachen erklären und bei Dehnen man mitlaufen kann!
Danke Area M für die unvergesslichen Erlebnisse!
- Sehr abwechslungsreiches Gelände mit vielen Gebäuden (welche alle bespielbar sind), Freiflächen und Wald
- Eintrittspreis für ein Tagesticket wurde mittlerweile auf 25€ pro Person angehoben
- mit Reservierung via Mail bekommt man für 40€ pro Tag einen der Teamräume
- es gibt keine Orga, man organisiert sich selbst und man muss sich mit den Paintballern austauschen (bzgl. Spielfläche) da es keine Spielfeldbegrenzungen gibt
- Französische Sprachkenntnisse sind von Vorteil, an der Anmeldung wird auch ein wenig Deutsch und Englisch gesprochen
0 Comment on this Article